Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
AFT PHARMACEUTICALS LIMITED (AFP)ASX AI Signals has generated 5 signal for AFP during the last 90 days, indicating active trading activity and ongoing AI monitoring
Latest AFP Signals | |
| 01/06/2026 | BUY |
| 31/05/2026 | BUY |
| 30/05/2026 | BUY |
AFP Share Price | |
| Current Price | $3.010 |
| 52 Week High | $3.300 |
| 52 Week Low: | $2.200 |
| Trading at (% of 52 Week High) | 91.21% |
AFT Pharmaceuticals Limited (ASX: AFP) is a global pharmaceutical company that develops, manufactures, and markets branded pharmaceutical products. The company focuses on providing over-the-counter and prescription medicines in areas such as respiratory, dermatology, pain management, and gastroenterology. AFT Pharmaceuticals operates in multiple international markets, including New Zealand, Australia, and Asia.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The BUY recommendation for AFT Pharmaceuticals Limited is supported by strong fundamentals and positive market sentiment, though some sector-specific risks remain.
Most readers would already know that AFT Pharmaceuticals' (NZSE:AFT) stock increased by 9.7% over the past three months. Given its impressive performance, we decided to study the company's key financial indicators as a company's long-term fundamentals usually dictate market outcomes. Particularly, w Key Insights
The projected fair value for AFT Pharmaceuticals is NZ$3.31 based on 2 Stage Free Cash Flow to Equity Current share price of NZ$3.80 suggests AFT Pharmaceuticals is potentially trading close to its fair value Our fair value estimate is 21% lower than AFT Pharmaceuticals' analyst price Key Insights
Significant insider control over AFT Pharmaceuticals implies vested interests in company growth 70% of the company is held by a single shareholder (Hartley Atkinson) Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a compan Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses is one path to excess returns. For example, long term AFT Pharmaceuticals Limited (NZSE:AFT) shareholders have enjoyed a 40% share price rise over the last half decade, well in exces Most readers would already know that AFT Pharmaceuticals' (NZSE:AFT) stock increased by 1.6% over the past week. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Particularly, we will be paying attention to AFT Pharmaceuticals' ROE toLatest AFT PHARMACEUTICALS LIMITED(AFP) News
Is AFT Pharmaceuticals Limited's (NZSE:AFT) Recent Performance Tethered To Its Attractive Financial Prospects?
Estimating The Fair Value Of AFT Pharmaceuticals Limited (NZSE:AFT)
Owning 70% in AFT Pharmaceuticals Limited (NZSE:AFT) means that insiders are heavily invested in the company's future
AFT Pharmaceuticals' (NZSE:AFT) investors will be pleased with their respectable 40% return over the last five years
Is AFT Pharmaceuticals Limited's (NZSE:AFT) Latest Stock Performance Being Led By Its Strong Fundamentals?
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial